MYC and ovarian cancer: Recently, therapeutic synergy for combination of PARPi and CDK4/6i has been demonstrated in MYC highly expressed breast and ovarian cancers with HR proficiency [22,23], which provides a new synthetic lethal strategy for treatment of these cancers regardless HR status.